Mukka Proteins Ltd Quality Parameters Deteriorate Amidst Challenging FMCG Landscape

Declining Growth Trends Raise Concerns

Over the past five years, Mukka Proteins has experienced a contraction in its top-line and operating profitability. Sales growth has declined at a compounded annual rate of -3.07%, while EBIT growth has fallen even more sharply at -4.98%. These negative growth rates contrast starkly with the broader FMCG sector, which has generally maintained positive expansion despite macroeconomic headwinds.

This slowdown in revenue and earnings growth undermines the company’s ability to generate sustainable cash flows and invest in future expansion. The negative trajectory also weighs on investor sentiment, as reflected in the stock’s 1-year return of -28.87%, significantly underperforming the Sensex’s 8.52% gain over the same period.

Leverage and Interest Coverage Signal Elevated Financial Risk

Mukka Proteins’ financial structure reveals heightened risk due to elevated debt levels. The average debt to EBITDA ratio stands at 4.93, indicating that the company’s earnings before interest, tax, depreciation and amortisation cover its debt obligations less than five times. This is a relatively high leverage level for an FMCG company, where stable cash flows are expected to support moderate debt.

Moreover, the EBIT to interest coverage ratio averages 2.87, suggesting that operating profits are only about 2.9 times the interest expense. While this is above the critical threshold of 1.5, it leaves limited cushion against earnings volatility or rising interest rates. The net debt to equity ratio of 1.25 further confirms a capital structure tilted towards debt, increasing financial vulnerability.

Returns on Capital Reflect Mediocre Operational Efficiency

Return on capital employed (ROCE) and return on equity (ROE) are key indicators of how effectively a company utilises its capital to generate profits. Mukka Proteins’ average ROCE is 10.29%, while ROE is 10.63%. These figures are modest and below the levels typically expected from high-quality FMCG firms, which often deliver ROCE and ROE in the mid-to-high teens.

The relatively low returns suggest that the company’s asset base and equity capital are not being deployed efficiently to create shareholder value. This inefficiency may stem from operational challenges, pricing pressures, or suboptimal capital allocation decisions.

Capital Turnover and Taxation

The sales to capital employed ratio, a measure of asset turnover, averages 1.33 for Mukka Proteins. This indicates that for every ₹1 of capital employed, the company generates ₹1.33 in sales, which is on the lower side for FMCG companies that typically benefit from higher asset turnover due to fast-moving inventory and distribution networks.

The tax ratio of 25.06% aligns with standard corporate tax rates, indicating no unusual tax burdens or benefits impacting profitability.

Shareholding and Pledging

Institutional holding in Mukka Proteins is minimal at 1.86%, reflecting limited interest from large investors. Notably, there are no pledged shares, which is a positive sign as it indicates promoters have not leveraged their holdings for debt, reducing the risk of forced selling.

Comparative Industry Positioning

Within its peer group, Mukka Proteins ranks below average in quality metrics. Competitors such as Apex Frozen Food maintain average quality grades, while others like Kings Infra achieve good ratings. Several peers, including Coastal Corporat and Waterbase, also fall into the below average category, indicating sector-wide challenges for some micro-cap FMCG players.

This relative positioning underscores the need for Mukka Proteins to address its operational and financial weaknesses to improve investor confidence and market standing.

Stock Price and Market Performance

At a current price of ₹24.86, Mukka Proteins is trading closer to its 52-week low of ₹20.20 than its high of ₹35.93, reflecting recent investor caution. The stock declined by 2.20% on the latest trading day, continuing a trend of underperformance relative to the broader market.

Short-term returns have been mixed, with a 1-month gain of 11.73% outperforming the Sensex’s -1.20%, but the 1-year return remains deeply negative at -28.87%. Year-to-date, the stock has gained 3.54%, while the Sensex has declined 3.04%, indicating some recent recovery attempts.

Mojo Score and Rating Update

MarketsMOJO has downgraded Mukka Proteins’ quality grade from average to below average as of 14 Nov 2025, with the overall Mojo Score now at 37.0, categorised as a Sell rating. This represents a downgrade from the previous Strong Sell grade, signalling a slight improvement in sentiment but still reflecting significant concerns about the company’s fundamentals.

The market capitalisation grade remains low at 4, consistent with the company’s micro-cap status and limited liquidity.

Outlook and Investor Considerations

Investors should approach Mukka Proteins with caution given the deteriorating quality parameters and financial metrics. The company’s negative sales and EBIT growth over five years, combined with elevated leverage and modest returns on capital, suggest operational and financial challenges that may constrain future performance.

While the downgrade from strong sell to sell indicates some stabilisation, the below average quality grade highlights the need for strategic initiatives to improve profitability, reduce debt, and enhance capital efficiency.

Comparatively low institutional ownership and limited market capitalisation further reduce liquidity and may increase volatility. Prospective investors should weigh these risks against potential recovery catalysts or sector tailwinds before committing capital.

In summary, Mukka Proteins currently exhibits fundamental weaknesses that justify a cautious stance, with a focus on monitoring improvements in growth, leverage reduction, and return metrics before considering a more positive investment thesis.

Unlock special upgrade rates for a limited period. Start Saving Now →